News

Women are notoriously underrepresented in health tech, which can have detrimental impacts on the industry as a whole.

The ePrescription is to be established in Germany by 2020. In April, German health minister Jens Spahn spoke at the DMEA 2019 (formerly conhIT) in Berlin about its benefits and opportunities in Germany. The German federal health minister discussed the possibilities of implementation and the added value resulting from ePrescription and other online services for digitising the German healthcare system together with representatives of the German Medical Association, the health insurance funds, the Federal Association of German mail-order pharmacies (BVDVA) and the German Telekom Healthcare and Security Solutions. Spahn evaded concerns about technical hurdles for the patients: German patients would not have to manage the ePrescription on their own. "In the ideal process, the ePrescription will be part of the electronic patient record," said Spahn. "The moment I am in the pharmacy with my electronic health card, the pharmacist can access it." Spahn also emphasised the health benefits of the e-prescription: "We will only gain acceptance for the electronic health record and digitisation among patients, physicians, pharmacists, and anyone else in healthcare when there is finally added value." That could change with the ePrescription, the minister added. "The ePrescription will bring real added value. If we combine it with online consultations or pharmacy delivery services, the range of services offered to patients will be extended to bring the digital component to healthcare,” he said. Therefore, in 2019, appropriate provisions will be made in the renewal of the German Medicines Act (AMG). In a January press release, the German Ministry of Health said that not only drug safety and patient safety should increase, but also the legal conditions for the paperless prescription of medicinal products - both during regular medical visits and telemedicine consultations. The ePrescription should, according to the experts, above all boost the mail-order pharmacy industry. The German market with currently two percent turnover in online drug sales could, for example, now approach the US market, with online sales already accounting for a good quarter of total business. Anna Engberg is a Wiesbaden-based freelance journalist specialising in health and technology.

Australia’s national science agency CSIRO and GenesisCare, one of Australia’s largest cancer care providers, today announced a A$5.1M research partnership which focuses on an emerging area of science called theranostics to develop new therapies against some of the most fatal and difficult-to-treat cancers affecting Australians. What’s it about According to the Theranostics Australia website, theranostics uses specific biological pathways in the human body, to acquire diagnostic images and also to deliver a therapeutic dose of radiation to the patient. A specific diagnostic test shows a particular molecular target on a tumour, allowing a therapy agent to specifically target that receptor on the tumour, rather than more broadly the disease and location it presents. Treatments successfully designed in the project will be trialled locally in Australia through GenesisCare's clinical network, giving Australian cancer patients access to new treatments sooner, rather than waiting for treatments to be developed and trialled overseas first. Access to this form of treatment has historically been limited globally, and it is hoped this investment may help spark a new theranostics industry in Australia to ultimately improve patient outcomes. GenesisCare is building a network of clinical centres to support research into new therapies, and is providing compassionate access to treatment for patients who have exhausted conventional treatments for prostate cancer. Currently GenesisCare offers theranostics treatment in Hurstville (New South Wales), Perth (Western Australia), on the Gold Coast (Queensland), and in Windsor (UK), with plans to introduce the treatment to more centres in 2019. The new research project forms part of CSIRO's Probing Biosystems Future Science Platform and builds on CSIRO's expertise in cancer biomarker research. What’s the trend Cancer remains the leading cause of death in Australia, with almost 50,000 deaths from cancer estimated in 2019, including 3051 deaths from pancreatic cancer, 1549 deaths from brain cancer, and 1046 deaths from ovarian cancer anticipated this year alone. On the record “We're targeting cancers that are currently the most 'untreatable', such as brain, pancreatic and ovarian cancers and metastatic cancers, because that's where we think we can make a profound difference,” CSIRO project lead Professor Stephen Rose said in a statement. “We’re exploring a very exciting approach called theranostic cancer treatment, which is a type of precision medicine that finds and attacks individual cancer cells in a person’s body – rather than attacking both cancerous and healthy cells.” Associate Professor Peter O'Brien, Chief Medical Officer at GenesisCare, said the project builds on research and ongoing clinical trials using theranostics. "We've seen a rapidly developing body of evidence in theranostics in prostate cancer and neuroendocrine tumours, and this partnership aims to accelerate the time it takes to bring findings from the lab to the clinic for other hard to treat cancers," he said. 

The radiology provider says up to 5,400 authorizations could be required per day. Automation of the process, while maintaining a human touch, has brought many efficiencies.

More and more health systems are taking steps to "fully unleash nurse innovators at the leadership level," a new report shows, tapping their specialized expertise for technology deployment, process improvement, patient experience and more.

Recursion releases more than 300 gigabytes of data it hopes will be a "playground" for innovative new machine learning applications.

It’s a matter of change management – and there are some applicable best practices.

Three representatives from their respective fields of AI – clinical practice, research and healthcare apps came together for a panel discussion around the current and future developments of AI in healthcare on the second day of the HIMSS Singapore eHealth & Health 2.0 Summit on April 24. The panel consisted of Dr Ali Parsa, Founder and CEO, Babylon Health, Dr Ngiam Kee Yuan, Group Chief Technology Officer, National University Health System, Singapore and Dr Hwang Hee, Chief Information Officer & Associate Professor, Department of Pediatrics, Seoul National University Bundang Hospital, South Korea. The hype cycle of AI in general and in healthcare Mr Neil Patel, President, Healthbox, Executive Vice President, HIMSS, USA, who was the panel moderator, began the discussion asking the panelists on their thoughts on the current hype cycle of AI broadly and in healthcare. “I think at the general level, we’re seeing a much greater update of machine learning and deep learning because of the availability of two things: one is the data that becomes available and secondly, relatively cheaper or cheap computing power that one can get today. That spurred a new revolution and allowed us to use information in ways we never thought possible. But it’s also created real challenges – one of the key things I tell every software developer is to ensure that the data is ‘clean’, that’s paramount. And I think from that point of view, we always have to think about AI with reference to the data we select,” said Dr Ngiam. He explained that the best way to describe ‘clean’ data is to reflect reality. In healthcare data, something is usually missing or there’s too much noise or extra data points that do not necessarily contribute to the desired outcome. Another way to look at it is that the data has to be appropriately selected for the specific purpose. For example, if the purpose is to predict the length of stay at a hospital, then the length of stay data has to be absolutely spot on and all the determinants of length of stay has to be within that dataset.  Citing from his experience in the varied use of AI in the Babylon Health app, Dr Parsa said: “I think we use the word AI for a whole set of different techniques. And each of those techniques are useful for different applications. For instance, for diagnosis, you cannot use what is currently called deep learning because the likelihood of misdiagnosis is very high and the technique to be used is probabilistic graphical modelling, which is very close to probability analysis – it just happens to be that machines are better at probability analysis that the human brain can be.” For Dr Parsa, the hype of AI is high and in the short-term, it will continue to do what it has done in the last few years but in the long-term it will surpass all the current imaginations. The observation by Dr Ngiam is that the healthcare vertical is lagging behind in the AI hype cycle compared to industries like finance and logistics. In healthcare, the use of AI is directly affecting patients so it has to bear the same standards as other medical devices that are currently in medical practice. AI technologies in healthcare are slightly overhyped but in terms of real adoption, there needs to be factors like a really mature EHR system, good data streams, finding ways to deploy these AI technologies and training doctors to ‘buy in’ into using these technologies. Augmenting, not replacing doctors There are reports or articles that get a lot of press, for instance, of AI algorithms being tested against real doctors and ‘beating’ the human doctors repeatedly. The debate of whether doctors are going to be ‘replaced’ by AI algorithms is also a polarising one. However, Dr Ngiam pointed out that one of the key principles that all can agree to is that AI tools are meant to augment, not replace doctors. “What we found which consistently (in studies) was that when the doctors took the machines’ suggestions, they were better than either the doctor or machine alone. I think that’s what we really want, that is, a combination of AI and a doctor is better than either of them.” Adding to Dr Ngiam’s statement, Dr Parsa said, “The augmentation (of AI) to existing services is unbelievably valuable and we should not underestimate the contribution technology makes today. The contribution it makes today makes those who use it significantly better than those who don’t, that in future, makes those who don’t use it, irrelevant.” Using AI to increase empathy From Dr Hwang’s personal experience as a clinician in South Korea, he feels that AI can help him concentrate more on his patients compared to the conventional way of practice. For example, he takes 30 minutes to an hour to do an electroencephalogram (EEG) interpretation compared to the AI software which just takes five minutes to do the same – that frees up more time for him to communicate with his patients.  One of the biggest complaints mentioned by Dr Ngiam is that doctors spend way too much time staring at screens and they may not be looking at patients sufficiently. He explained that AI can help doctors transact a consult with the empathy that is required or that patients want from a doctor – AI can help with the hard work of summarising of key points, so that doctors are better prepared to meet with the patient, rather than for them to read off a screen.  During one of the Babylon app tests, Dr Parsa found out that it was possible to reduce the time of consultation from 10 minutes to about five minutes, which would increase the satisfaction of patients. However, his 16-year old son who also did some of the tests – found that it was not very good as he had to repeat answering the doctor’s questions after he had answered the same questions via the app.  Dr Parsa’s point was to think about the changing perceptions of humans: “For the first time in history, an 18-year old in Singapore, Korea, Iran, India, the US and the UK are closer to each other in their mentality and culture than they are compared to the past – that had never happened before. You now have a generation of human beings that behave globally in a very similar manner.  That generation does not want to spend two hours or wait for a few days to see a doctor or get a surgery, and being asked the same questions over and over again, that’s just not the way they were brought up. And we need to be very careful not to forget that shifting human culture, which is very significant.”

"Telemedicine optimizes our practice's capabilities, and also improves our patients' outcomes," said Dr. Robert S. Kaufmann of the internal med practice.

The MediLedger project, led by San Francisco blockchain startup Chronicled, is focused on leveraging DLT for more efficient healthcare contract reconciliation and chargeback processes.